Exxel Pharma Inc. (EXXL)
Exxel Pharma will go public soon, but the exact IPO date is still unknown.
Stock Price: Pending
IPO price not available yet
Chart not available yet
Data will show when the stock starts trading.
| Market Cap | n/a |
| Revenue (ttm) | 225,000 |
| Net Income (ttm) | -1.27M |
| Shares Out | 7.99M |
| EPS (ttm) | -0.16 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | n/a |
| Previous Close | n/a |
| Day's Range | n/a |
| 52-Week Range | n/a |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About EXXL
Exxel Pharma Inc. is a biopharmaceutical company focused on developing novel therapeutics for the treatment of neuronal hypersensitivity disorders. We are developing EX937, our lead product candidate, for refractory chronic cough (RCC) and other hypersensitivity disorders that share the pathophysiology of hypersensitized sensory neurons. Investigational New Drug enabling studies supporting our early clinical development program (ERCP) have been completed and we target the first-in-human (FIH) dosing in 2026, pending capitalization and completio... [Read more]
Industry Biotechnology
Sector Healthcare
Founded 2018
Employees 1
Stock Exchange NYSEAMERICAN
Ticker Symbol EXXL
Website https://exxelpharma.com/
Financial Performance
Financial StatementsNews
Exxel Pharma IPO Registration Document (S-1)
Exxel Pharma has filed to go public with an IPO on the NYSE American
4 weeks ago - SEC